Cargando…

CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions

Palbociclib, ribociclib, and abemaciclib belong to the third generation of cyclin-dependent kinases inhibitors (CDKis), an established therapeutic class for advanced and metastatic breast cancer. Interindividual variability in the therapeutic response of CDKis has been reported and some individuals...

Descripción completa

Detalles Bibliográficos
Autores principales: Roncato, Rossana, Angelini, Jacopo, Pani, Arianna, Cecchin, Erika, Sartore-Bianchi, Andrea, Siena, Salvatore, De Mattia, Elena, Scaglione, Francesco, Toffoli, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7504705/
https://www.ncbi.nlm.nih.gov/pubmed/32883002
http://dx.doi.org/10.3390/ijms21176350
_version_ 1783584685293568000
author Roncato, Rossana
Angelini, Jacopo
Pani, Arianna
Cecchin, Erika
Sartore-Bianchi, Andrea
Siena, Salvatore
De Mattia, Elena
Scaglione, Francesco
Toffoli, Giuseppe
author_facet Roncato, Rossana
Angelini, Jacopo
Pani, Arianna
Cecchin, Erika
Sartore-Bianchi, Andrea
Siena, Salvatore
De Mattia, Elena
Scaglione, Francesco
Toffoli, Giuseppe
author_sort Roncato, Rossana
collection PubMed
description Palbociclib, ribociclib, and abemaciclib belong to the third generation of cyclin-dependent kinases inhibitors (CDKis), an established therapeutic class for advanced and metastatic breast cancer. Interindividual variability in the therapeutic response of CDKis has been reported and some individuals may experience increased and unexpected toxicity. This narrative review aims at identifying the factors potentially concurring at this variability for driving the most appropriate and tailored use of CDKis in the clinic. Specifically, concomitant medications, pharmacogenetic profile, and pathophysiological conditions could influence absorption, distribution, metabolism, and elimination pharmacokinetics. A personalized therapeutic approach taking into consideration all factors potentially contributing to an altered pharmacokinetic/pharmacodynamic profile could better drive safe and effective clinical use.
format Online
Article
Text
id pubmed-7504705
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75047052020-09-26 CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions Roncato, Rossana Angelini, Jacopo Pani, Arianna Cecchin, Erika Sartore-Bianchi, Andrea Siena, Salvatore De Mattia, Elena Scaglione, Francesco Toffoli, Giuseppe Int J Mol Sci Review Palbociclib, ribociclib, and abemaciclib belong to the third generation of cyclin-dependent kinases inhibitors (CDKis), an established therapeutic class for advanced and metastatic breast cancer. Interindividual variability in the therapeutic response of CDKis has been reported and some individuals may experience increased and unexpected toxicity. This narrative review aims at identifying the factors potentially concurring at this variability for driving the most appropriate and tailored use of CDKis in the clinic. Specifically, concomitant medications, pharmacogenetic profile, and pathophysiological conditions could influence absorption, distribution, metabolism, and elimination pharmacokinetics. A personalized therapeutic approach taking into consideration all factors potentially contributing to an altered pharmacokinetic/pharmacodynamic profile could better drive safe and effective clinical use. MDPI 2020-09-01 /pmc/articles/PMC7504705/ /pubmed/32883002 http://dx.doi.org/10.3390/ijms21176350 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Roncato, Rossana
Angelini, Jacopo
Pani, Arianna
Cecchin, Erika
Sartore-Bianchi, Andrea
Siena, Salvatore
De Mattia, Elena
Scaglione, Francesco
Toffoli, Giuseppe
CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions
title CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions
title_full CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions
title_fullStr CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions
title_full_unstemmed CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions
title_short CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions
title_sort cdk4/6 inhibitors in breast cancer treatment: potential interactions with drug, gene, and pathophysiological conditions
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7504705/
https://www.ncbi.nlm.nih.gov/pubmed/32883002
http://dx.doi.org/10.3390/ijms21176350
work_keys_str_mv AT roncatorossana cdk46inhibitorsinbreastcancertreatmentpotentialinteractionswithdruggeneandpathophysiologicalconditions
AT angelinijacopo cdk46inhibitorsinbreastcancertreatmentpotentialinteractionswithdruggeneandpathophysiologicalconditions
AT paniarianna cdk46inhibitorsinbreastcancertreatmentpotentialinteractionswithdruggeneandpathophysiologicalconditions
AT cecchinerika cdk46inhibitorsinbreastcancertreatmentpotentialinteractionswithdruggeneandpathophysiologicalconditions
AT sartorebianchiandrea cdk46inhibitorsinbreastcancertreatmentpotentialinteractionswithdruggeneandpathophysiologicalconditions
AT sienasalvatore cdk46inhibitorsinbreastcancertreatmentpotentialinteractionswithdruggeneandpathophysiologicalconditions
AT demattiaelena cdk46inhibitorsinbreastcancertreatmentpotentialinteractionswithdruggeneandpathophysiologicalconditions
AT scaglionefrancesco cdk46inhibitorsinbreastcancertreatmentpotentialinteractionswithdruggeneandpathophysiologicalconditions
AT toffoligiuseppe cdk46inhibitorsinbreastcancertreatmentpotentialinteractionswithdruggeneandpathophysiologicalconditions